What the July 2026 FDA Advisory Committee Meetings on Compounded Peptides Mean for Healthcare Businesses

The meetings generated significant discussion across the healthcare industry, particularly among pharmacies, telehealth providers, prescribers, and businesses involved in peptide therapies. While the committee’s recommendations represent an important milestone in the regulatory process, they do not change the current legal or compliance landscape at this time.

Here’s what happened, what it means today, and what businesses should be watching in the months ahead.

What Did the Committee Review?

During the two-day meeting, PCAC evaluated available scientific and regulatory information for the following peptide substances:

• BPC-157 (acetate and free base)
• KPV (acetate and free base)
• TB-500 (acetate and free base)
• MOTs-C (acetate and free base)
• DSIP (Emideltide) (acetate and free base)
• Semax (acetate and free base)
• Epitalon (acetate and free base)

The committee considered whether each substance should be recommended for inclusion on the Section 503A Bulk Drug Substances List — a list of ingredients that may be eligible for use in compounded preparations by qualifying 503A pharmacies if additional statutory requirements are met.

Based on the committee’s votes, members recommended that all of these peptides be added to the list. However, these votes should not be interpreted as an immediate change in FDA policy or federal law.

Understanding the Role of the Pharmacy Compounding Advisory Committee

One of the most important takeaways from these meetings is understanding what PCAC does — and what it does not do.

The committee serves as an advisory body to the FDA. Its role is to review scientific evidence and provide recommendations, but it does not establish regulatory policy or amend federal regulations. As the FDA explains, advisory committees provide advice and recommendations, while the agency retains full regulatory decision-making authority.

In other words, even if the committee recommends that a substance should be eligible for compounding, that recommendation alone does not authorize compounding or change existing regulatory requirements.

What Does This Mean Today?

For healthcare businesses, the practical answer is straightforward: Nothing changes today.

The peptides discussed during the July meetings remain outside the current Section 503A Bulk Drug Substances List. They also are not the subject of applicable USP or National Formulary monographs and are not components of FDA-approved drug products. Meeting one or more of these criteria is an essential requirement for compounding under Section 503A of the FD&C Act. As a result, they remain ineligible for routine compounding under the current regulatory framework.

Until the FDA completes any future regulatory action, businesses should continue evaluating their operations according to the regulations currently in effect—not the advisory committee’s recommendations.

This distinction is particularly important because discussions surrounding advisory committee meetings can sometimes create the impression that regulatory requirements have already changed. They have not.

What Happens Next?

The committee’s recommendations are only one step in a much longer regulatory process.

If the FDA decides to move forward with the committee’s recommendations, the agency would generally begin formal rulemaking by publishing a Notice of Proposed Rulemaking (NPRM) in the Federal Register. That proposal would identify the substances the FDA is considering adding to the Section 503A Bulk Drug Substances List.

The proposed rule would then enter a public comment period typically lasting 60 to 90 days, during which healthcare professionals, pharmacies, manufacturers, industry organizations, and other stakeholders would have an opportunity to submit comments.

Only after reviewing those comments would the FDA determine whether to publish a final rule. If a final rule is issued adding a substance to the Section 503A list, it is only at that point that the regulatory framework governing that substance would change.

This process helps ensure that significant regulatory decisions are informed not only by advisory committee recommendations but also by broader scientific, clinical, and public input.

An Important Distinction: 503A Pharmacy Focus

One important point that is easy to overlook is that the July advisory committee meetings focused only on the FDA’s Section 503A Bulk Drug Substances List.

This means the committee’s recommendations apply only to 503A compounding pharmacies, which are traditional state-licensed pharmacies that compound medications pursuant to patient-specific prescriptions.

The discussions do not apply to 503B outsourcing facilities, which operate under a separate section of the Federal Food, Drug, and Cosmetic Act and are subject to a different regulatory framework.

As a result, even if the FDA ultimately decides to add any of these peptides to the 503A Bulk Drug Substances List, that change would not automatically make them eligible for compounding by 503B outsourcing facilities. Separate regulatory requirements would continue to apply to those facilities.

For businesses that work with both 503A pharmacies and 503B outsourcing facilities, understanding this distinction is important because the regulatory requirements for these two types of compounders are not the same.

What This Means for LegitScript Certification

At LegitScript, monitoring regulatory developments like these is a core part of maintaining a certification program that reflects the current healthcare regulatory landscape.

Although the July advisory committee meetings have generated considerable industry interest, the recommendations themselves do not change LegitScript Certification Standards because they do not change the underlying regulatory framework.

Should the FDA ultimately adopt any regulatory changes through its formal rulemaking process, LegitScript will carefully evaluate those changes, determine whether updates to our certification review processes are appropriate, and communicate any resulting impacts to applicants and certified clients.

Our role is to help businesses navigate an increasingly complex regulatory environment by continuously monitoring developments from agencies such as the FDA and FTC and ensuring our Certification Standards remain aligned with current laws, regulations, and regulatory guidance.

As the regulatory landscape continues to evolve, businesses must remain grounded in today’s regulatory requirements while preparing for tomorrow’s changes. LegitScript will continue to closely monitor developments from the FDA and other regulators, evaluate their potential impact, and provide timely guidance to help the industry navigate an increasingly complex compliance environment.